Compare Recursion Pharmaceuticals Inc (RXRX) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Sezzle Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.23 (market cap $1.86B), while Sezzle Inc trades at $118.51 (market cap $3.99B). The key difference: Sezzle Inc is far larger — about 2.1× Recursion Pharmaceuticals Inc's market cap, and Sezzle Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | SEZL | |
|---|---|---|
Market Cap | $1.86B | $3.99B |
Sector | Health | Technology |
52-Week High | $6.79 | $188.55 |
52-Week Low | $2.84 | $50.97 |
Enterprise Value | $1.38B | $4.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
SEZL trades at $118.35, down 1.85% on the day, with technical indicators showing bearish momentum. The company demonstrates strong fundamentals with 30.35% net income margin and consistent earnings beats in recent quarters. Recent business developments include merchant network expansion with Gymshark and Debenhams Group, while analyst consensus remains bullish with a $161.17 price target representing 36% upside potential.
SEZL presents a compelling growth story with robust profitability metrics and expanding market presence, though technical weakness and high valuation multiples warrant caution. The stock offers significant upside based on analyst targets but faces execution risks in competitive fintech landscape and potential market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
